Denali Therapeutics (DNLI) Competitors

Denali Therapeutics logo
$18.08 -0.66 (-3.52%)
Closing price 04:00 PM Eastern
Extended Trading
$18.09 +0.01 (+0.06%)
As of 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DNLI vs. BEAM, SMMT, KYMR, BMRN, and PCVX

Should you buy Denali Therapeutics stock or one of its competitors? Denali Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), Summit Therapeutics (SMMT), Kymera Therapeutics (KYMR), BioMarin Pharmaceutical (BMRN), and Vaxcyte (PCVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Denali Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -73.04%. Beam Therapeutics' return on equity of -32.76% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-73.04% -32.76% -25.80%
Denali Therapeutics N/A -54.94%-42.15%

In the previous week, Beam Therapeutics had 9 more articles in the media than Denali Therapeutics. MarketBeat recorded 24 mentions for Beam Therapeutics and 15 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 0.73 beat Denali Therapeutics' score of 0.60 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Denali Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Beam Therapeutics presently has a consensus price target of $47.64, suggesting a potential upside of 108.35%. Denali Therapeutics has a consensus price target of $35.71, suggesting a potential upside of 90.58%. Given Beam Therapeutics' higher probable upside, equities analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

Beam Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A
Denali Therapeutics$330.53M9.09-$512.54M-$1.73N/A

Summary

Beam Therapeutics beats Denali Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Summit Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 81.8% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Denali Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$330.53M9.09-$512.54M-$1.73N/A
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A

Denali Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.49, suggesting that its share price is 249% less volatile than the broader market.

Denali Therapeutics' return on equity of -54.94% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Denali TherapeuticsN/A -54.94% -42.15%
Summit Therapeutics N/A -138.82%-117.11%

In the previous week, Denali Therapeutics had 8 more articles in the media than Summit Therapeutics. MarketBeat recorded 15 mentions for Denali Therapeutics and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.99 beat Denali Therapeutics' score of 0.60 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Denali Therapeutics currently has a consensus target price of $35.71, indicating a potential upside of 90.58%. Summit Therapeutics has a consensus target price of $28.61, indicating a potential upside of 102.17%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Denali Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82
Summit Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58

Summary

Denali Therapeutics beats Summit Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Denali Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Denali Therapeutics had 11 more articles in the media than Kymera Therapeutics. MarketBeat recorded 15 mentions for Denali Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.07 beat Denali Therapeutics' score of 0.60 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Denali Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Denali Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -22.39% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -22.39% -20.48%
Denali Therapeutics N/A -54.94%-42.15%

92.9% of Denali Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kymera Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$102.24M106.53-$311.35M-$3.62N/A
Denali Therapeutics$330.53M9.09-$512.54M-$1.73N/A

Kymera Therapeutics has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Kymera Therapeutics presently has a consensus price target of $139.16, suggesting a potential upside of 9.09%. Denali Therapeutics has a consensus price target of $35.71, suggesting a potential upside of 90.58%. Given Denali Therapeutics' higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

Summary

Kymera Therapeutics beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Denali Therapeutics had 6 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Denali Therapeutics and 9 mentions for BioMarin Pharmaceutical. Denali Therapeutics' average media sentiment score of 0.60 beat BioMarin Pharmaceutical's score of 0.35 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioMarin Pharmaceutical
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Denali Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Denali Therapeutics has a net margin of 0.00% compared to BioMarin Pharmaceutical's net margin of -0.52%. BioMarin Pharmaceutical's return on equity of 5.58% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical-0.52% 5.58% 3.51%
Denali Therapeutics N/A -54.94%-42.15%

BioMarin Pharmaceutical has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

BioMarin Pharmaceutical presently has a consensus target price of $87.22, suggesting a potential upside of 52.40%. Denali Therapeutics has a consensus target price of $35.71, suggesting a potential upside of 90.58%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than BioMarin Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioMarin Pharmaceutical has higher revenue and earnings than Denali Therapeutics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$3.22B3.44$348.90M-$0.10N/A
Denali Therapeutics$330.53M9.09-$512.54M-$1.73N/A

Summary

Denali Therapeutics beats BioMarin Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Denali Therapeutics has higher revenue and earnings than Vaxcyte. Denali Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$766.63M-$8.06N/A
Denali Therapeutics$330.53M9.09-$512.54M-$1.73N/A

Vaxcyte currently has a consensus price target of $110.50, suggesting a potential upside of 74.37%. Denali Therapeutics has a consensus price target of $35.71, suggesting a potential upside of 90.58%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Vaxcyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

Vaxcyte has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

In the previous week, Denali Therapeutics had 3 more articles in the media than Vaxcyte. MarketBeat recorded 15 mentions for Denali Therapeutics and 12 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.88 beat Denali Therapeutics' score of 0.60 indicating that Vaxcyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Denali Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vaxcyte's return on equity of -42.04% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -42.04% -36.82%
Denali Therapeutics N/A -54.94%-42.15%

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Denali Therapeutics beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DNLI vs. The Competition

MetricDenali TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.90B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-10.4524.2434.3430.11
Price / Sales8.7714.858.005.32
Price / CashN/A21.8921.0222.34
Price / Book2.624.354.763.85
Net Income-$512.54M-$24.19M$3.52B$393.14M
7 Day Performance-11.07%-7.26%-5.34%-4.53%
1 Month Performance2.67%-4.96%-3.61%-5.86%
1 Year Performance3.67%-2.87%0.01%-7.78%

Denali Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNLI
Denali Therapeutics
3.7644 of 5 stars
$18.08
-3.5%
$35.71
+97.5%
+7.5%$2.90B$330.53MN/A507
BEAM
Beam Therapeutics
2.743 of 5 stars
$27.02
+2.3%
$47.36
+75.3%
+5.3%$2.88B$139.74MN/A540
SMMT
Summit Therapeutics
2.6535 of 5 stars
$17.84
+9.2%
$28.61
+60.4%
-21.5%$12.93BN/AN/A265
KYMR
Kymera Therapeutics
2.1601 of 5 stars
$138.86
+5.4%
$139.16
+0.2%
+96.4%$11.63B$39.21MN/A285
BMRN
BioMarin Pharmaceutical
4.1822 of 5 stars
$57.18
+2.1%
$87.91
+53.7%
+4.6%$11.07B$3.22B32.103,221

Related Companies and Tools


This page (NASDAQ:DNLI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners